Aclaris Therapeutics Inc (NASDAQ:ACRS) had its price target hoisted by Guggenheim from $35.00 to $40.00 in a report released on Wednesday. The brokerage currently has a buy rating on the stock.

ACRS has been the subject of a number of other reports. Zacks Investment Research downgraded Aclaris Therapeutics from a buy rating to a hold rating in a report on Thursday, March 2nd. Jefferies Group LLC reiterated a buy rating and issued a $32.00 target price (up from $29.00) on shares of Aclaris Therapeutics in a report on Friday, November 18th. Finally, Leerink Swann assumed coverage on Aclaris Therapeutics in a report on Tuesday, November 29th. They issued an outperform rating for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $36.25.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 28.88 on Wednesday. Aclaris Therapeutics has a 12-month low of $14.12 and a 12-month high of $33.25. The firm’s market cap is $618.96 million. The stock has a 50 day moving average price of $28.79 and a 200 day moving average price of $26.33.

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/21/guggenheim-increases-aclaris-therapeutics-inc-acrs-price-target-to-40-00.html

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, March 15th. The company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.10. On average, equities analysts expect that Aclaris Therapeutics will post ($3.11) earnings per share for the current year.

Your IP Address:

In other news, Director Anand Mehra sold 750,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 10th. The stock was sold at an average price of $28.25, for a total transaction of $21,187,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Ventures Fund Vii L.P. Vivo sold 425,000 shares of the business’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $30.82, for a total value of $13,098,500.00. The disclosure for this sale can be found here. Insiders own 46.40% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC bought a new stake in Aclaris Therapeutics during the fourth quarter valued at $34,219,000. Rock Springs Capital Management LP increased its stake in Aclaris Therapeutics by 1.6% in the third quarter. Rock Springs Capital Management LP now owns 1,016,000 shares of the company’s stock valued at $26,020,000 after buying an additional 16,000 shares during the period. Marshall Wace LLP increased its stake in Aclaris Therapeutics by 286.4% in the fourth quarter. Marshall Wace LLP now owns 466,734 shares of the company’s stock valued at $12,667,000 after buying an additional 345,934 shares during the period. EcoR1 Capital LLC bought a new stake in Aclaris Therapeutics during the fourth quarter valued at $11,236,000. Finally, Deerfield Management Co. increased its stake in Aclaris Therapeutics by 223.3% in the fourth quarter. Deerfield Management Co. now owns 375,000 shares of the company’s stock valued at $10,178,000 after buying an additional 259,000 shares during the period. Hedge funds and other institutional investors own 61.94% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

5 Day Chart for NASDAQ:ACRS

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.